Clinical Trial Update: Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer That Overexpresses HER2 [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated trastuzumab for HER2-overexpressing stage IIIB or stage IV non-small cell lung cancer; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED